KEYNOTE 564: 12m adjuvant pembrolizumab vs placebo ccRCC – high recurrence risk pT2 (G4, sarcomatoid) 6.0% pT≥3 91.3% pTanyN+ 6.2% Resected M1 NED 5.8%